Legend Biotech Crosses the Profitability Rubicon and Doubles Down on In Vivo

First adjusted net income, 50% top-line growth, and an in vivo CAR-T platform that could upend the blood cancer market.

LEGN · Earnings Call · 2026-08-11

A New Chapter: Leadership Transition Meets Financial Milestone

Legend Biotech's second-quarter report wasn't just another earnings beat—it was a strategic inflection point. The company delivered its first quarter of company-wide profitability on both IFRS and adjusted bases, with adjusted net income of $63 million and revenue of approximately $657 million, up 50% year-over-year. This achievement comes amid a leadership transition: Ying Huang stepped down as CEO, with Alan Bash stepping in as Interim CEO.

We want to be very clear. This is a leadership transition, not a strategy transition.
Alan Bash, Interim Chief Executive Officer · 2026-08-11

That framing matters because investors often fear disruption during C-suite changes, yet the company's priorities remain intact: maximize cell therapy franchise CARVYKTI, advance the next-generation pipeline, and execute with discipline. The numbers back that confidence. “This now marks a major milestone objective for Legend as the first quarter of company-wide profitability on both an IFRS and an adjusted basis.” — Carlos Santos, Chief Financial Officer · 2026-08-11 Operating margin swung to positive 15% from negative 9% a year earlier, a dramatic shift that validates the operating leverage in the manufacturing network. CARVYKTI global sales grew 50% year-over-year, with ex-U.S. sales surging 128%. The company also raised $212 million in an opportunistic equity offering, leaving it with ~$965 million in cash and no long-term debt—a balance sheet that now supports both commercial scale and pipeline investment.

The In Vivo Pivot: From One Product to a Platform

The most consequential development may be the early clinical data for LB2501, the company's CD19/CD20 dual-targeting in vivo CAR-T therapy for non-Hodgkin's lymphoma. Presented at EHA in June, the Phase I data showed a 100% objective response rate and 83.3% complete response rate at dose level 2 across six patients with B-cell malignancies. “We had compelling results at dose level 2, achieving a 100% objective response rate and an 83.3% complete response rate...” — Alan Bash, Interim Chief Executive Officer · 2026-08-11 Even more striking was the persistence of engineered T cells in peripheral blood for up to 116 days, suggesting that the platform can generate durable, functional CAR-T cells entirely inside the patient—a potential paradigm shift. Management is now positioning Legend not just as a CARVYKTI company but as a broader vivo platform player. Beyond LB2501, they've initiated an investigator-initiated trial for LB2505, a BCMA-targeted in vivo therapy for multiple myeloma, under the terms of the collaboration with J&J. They are also exploring expansion into Solid tumors—a notoriously difficult area—with DLL3 and other targets. This pivot is deliberate: earlier calls emphasized in vivo as a “transformative potential” (from the 2026-03-10 call), but now they have human proof-of-concept.

LB2102 (DLL3 autologous CAR-T) showed an ORR of 28.6% at higher dose levels in small cell lung cancer—encouraging for a solid tumor setting.

Financial Discipline and the Path to Scale

The profitability story is underpinned by disciplined cost management. R&D expenses declined 2% year-over-year as late-stage BCMA studies wind down, while SG&A grew only 19%—both well below revenue growth. Gross margin on net product sales hit 58% in Q2, but management guided for lower-50s in Q3 and mid-50s in Q4, reflecting the mix shift toward outpatient administration and potential quarterly volatility. Still, they see a clear path to 75% gross margin over time as manufacturing utilization scales. A notable new line item is income tax. For the first time, Legend recorded a meaningful tax expense of $22.3 million, driven by profitability across U.S., Belgian, and Chinese entities. They are negotiating a unilateral advanced pricing agreement with Chinese tax authorities and expect a tax rate in the high-20s range going forward. This is a mature sign of a company entering sustained profitability.
On capital allocation, Carlos Santos was explicit: the equity raise was opportunistic, aimed at accelerating the in vivo platform. “We expect to fully settle that liability this year.” — Carlos Santos, Chief Financial Officer · 2026-08-11 That refers to the ~$300 million loan from J&J, which will free up future cash flow. The company reaffirmed adjusted net income profitability for the second half of 2026 and expects sequential revenue growth in both Q3 and Q4. This echoes earlier guidance: in the 2026-03-10 call, Ying Huang said, “we are planning and also we're committed to sequential growth throughout the year” — Ying Huang, Chief Executive Officer · 2026-03-10, and in May, Alan Bash confirmed, “we do expect to see sequential growth quarter-on-quarter, both in the U.S. and OUS for the remainder of this year.” — Alan Bash, Chief Commercial Officer · 2026-05-12 The confluence is powerful: a proven commercial asset (CARVYKTI) generating cash, a next-generation in vivo platform with early efficacy, and a balance sheet that can fund both. Legend is no longer just a one-drug story—it's transitioning into a platform company with the potential to redefine CAR-T therapy across diseases. The market will be watching the IND filing for LB2501 and the next data readouts with intense interest.